Author: Customer Service

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) — We are advised by Blue Gold Limited that journalists and other readers should disregard the news release, Nasdaq-Listed Blue Gold Limited (BGL) Announces Updated Analyst Price Target of Up to $22, issued Dec. 18, 2025, over GlobeNewswire.

PERTH, Western Australia, Dec. 18, 2025 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKEF) (‘Alkane’ or ‘the Company’) is pleased to announce the latest exploration results for depth drilling at the Storheden Deposit at its Björkdal Operation in northern Sweden. Program SummaryThe Storheden deposit is situated approximately 600m to the north of the active Björkdal mine that has produced 1.66M oz of gold since 1988 and has 1.40M oz in Measured and Indicated Mineral Resources as at 30 June 2025 (20.35 Mt grading 2.14 g/t gold).1 Drilling over two recent campaigns has focussed on the depth testing and potential resource extension below the initial Inferred Mineral Resource for the Storheden Deposit estimated in 2025 of approximately 99koz (1,769 Kt at 1.74 g/t gold).1 Gold baring quartz veins have been...

VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) — LEEF Brands, Inc. (CSE: LEEF, OTCQB: LEEEF) (“LEEF” or the “Company”), a leading multi-state operator, today commented on the issuance of an executive order by President Donald Trump directing agencies to begin the rescheduling of cannabis under the U.S. Controlled Substances Act. The executive order initiates the reclassification of cannabis from Schedule I to Schedule III, removing it from the most restrictive category under federal law. This will improve operating economics for licensed operators, enable expanded medical research, and further the normalization of the regulated cannabis industry. “Cannabis rescheduling is a meaningful and long-awaited step forward for patients, research, and operators,” said Micah Anderson, Chief Executive Officer of LEEF Brands. “For...

GRAND RAPIDS, Mich., Dec. 18, 2025 (GLOBE NEWSWIRE) — Xtreme One Entertainment, Inc. (OTCID: XONI), a leading innovator in live sports and entertainment and the parent company of Xtreme Fighting Championships (XFC), today announced the completion of its report on the audited financial statements of Xtreme One Entertainment, Inc. for the years ended December 31, 2024 and 2023, by its auditors, Chicago-based L J Soldinger Associates, LLC. This milestone represents a key inflection point in the Company’s strategic growth plan and unlocks its uplisting to the OTCQB National Market. Completion of the exhaustive audit process satisfies one of the final eligibility requirements for OTCQB listing as well as Xtreme One’s upsized $25 million equity offering, reinforcing the Company’s commitment to enhanced financial transparency, disciplined...

LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast of the presentation will be accessible here and on the Events & Presentations section of Mesa Lab’s Investor Relations website at https://investors.mesalabs.com/. An archived replay of the webcast will be available through the same link following the presentation. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools...

Melbourne, Australia, Dec. 18, 2025 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” and the “Company”) (Nasdaq NVA, NVAWW) (ASX: NVA)(FRA: QM3)), a gold, antimony and critical minerals exploration stage company focused on advancing the Estelle Gold and Critical Minerals Project in Alaska, today announced the pricing of an underwritten public offering of 2,928,300 American Depositary Shares (“ADS“), with an ADS-to-ordinary-share ratio of 1 to 12, at a price to the public of $6.83 per ADS, for gross proceeds of approximately $20,000,000, before deducting underwriting discounts and offering expenses. In addition, Nova has granted the underwriters a 45-day option to purchase up to an additional 439,245 ADSs to cover over-allotments, if any. The Company intends to use the proceeds for planned exploration and development activities...

DENVER, Dec. 18, 2025 (GLOBE NEWSWIRE) — ArrowMark Financial Corp. (Nasdaq: BANX) (“ArrowMark” or the “Fund”) today announced that it has entered into a securities purchase agreement with investors to purchase 673,249 of its shares of common stock, in a registered direct offering. The purchase price for one share of common stock was $22.28. The Net Asset Value at the time of the transaction was $22.20. The registered direct offering is accretive to current shareholders. The proceeds from the registered direct offering are expected to be $14,999,987.72, exclusive of legal and administrative expenses associated with the transaction. ArrowMark anticipates that the net proceeds will be invested in accordance with its investment strategy. The securities described above are being offered pursuant to a “shelf” registration statement (File...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia and WILMINGTON, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FRANKFURT: LD2), a leading technology provider of AI-based next generation detection solutions for concealed weapons and threats, is pleased to announce that it is amending the terms of its non-brokered private placement (the “Offering”) previously announced on December 2, 2025 and December 12, 2025. The amended Offering will be for a minimum of 6,818,182 units (“Units”) and up to a maximum of 13,636,364 Units at a price of $0.22 per Unit for minimum gross proceeds of approximately $1,500,000 up to maximum gross proceeds of approximately $3,000,000. Each Unit will consist of one common...

Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to exercise its exclusive option to license Nxera’s GPR52 agonist program for schizophrenia, including the Phase 2 ready lead compound NXE0048149 (“NXE’149”). No further information was provided by Boehringer Ingelheim. All rights to the GPR52 portfolio will revert in full to Nxera Pharma together with all data and intellectual property generated under the collaboration in accordance with the terms of the Collaboration and License Option Agreement. NXE’149 and other GPR52 agonists within the portfolio were designed by Nxera using its world-leading NxWave™ structure-based drug design platform to improve patient outcomes by simultaneously...